GAITHERSBURG, Md., Sept. 2, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious
Use of GeNeuro's temelimab as part of the first personalized medicine approach in severe post-COVID neuropsychiatric syndromes Biomarker-based study to detect the presence of the pathogenic
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaMinjuvi
With this approval, BRUKINSA is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:
The second dose of the vaccine can be administered, at the earliest, two months after the first dose, Swissmedic said in a statement. 'We have more work to do,' Biden says as Omicron surge looms U.S. President Joe Biden on Monday pledged to ease a shortage of COVID-19 tests as the Omicron variant threatened to overwhelm hospitals and stifle travel plans as it spread across U.S. states this holiday week.